Navigation Links
Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
Date:4/10/2008

SAN FRANCISCO, April 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that positive preclinical and clinical results for its pipeline programs will be presented at numerous medical and scientific meetings over the coming months. These presentations will highlight Nektar's novel therapeutic candidates in the areas of oncology, anti-infectives and central nervous system (CNS), which leverage Nektar's innovative small molecule PEGylation and liquid aerosol platforms.

The data presentations are as follows:

-- April 12-16, 2008: Presentation of Positive Preclinical Data for NKTR-102 (PEG-irinotecan) at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California:

Poster #766: "Enhanced anti-tumor activity of NKTR-102, a novel

PEGylated-irinotecan, when administered in combination with

bevacizumab in a mouse model of human colorectal tumors"

Poster #5741: "NKTR-102, a novel PEGylated-irinotecan, has an

enhanced pharmacokinetic profile with reduced gastrointestinal and

hematopoietic toxicity compared to irinotecan with repeat dosing"

Poster #5742: "NKTR-102, a novel PEGylated-irinotecan, has a

superior acute safety, tolerability, and pharmacokinetic profile

compared to irinotecan"

-- May 8-10, 2008: Presentation of Phase 1 Clinical Trial Multi-Dose Safety Data for NKTR-118 (oral PEG-naloxol) in Opioid Bowel Dysfunction at the American Pain Society (APS) Meeting in Tampa, Florida:

Poster #210: "Results from a phase I, double-blind, randomized,

placebo-controlled, multiple-dose study evaluating the safety,

t
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
4. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
5. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
6. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
7. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
8. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
9. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/18/2013)... MENLO PARK, Calif. and INGELHEIM, ... -- Boehringer Ingelheim and Circuit Therapeutics have entered into ... new ways of treating psychiatric disorders.  Circuit Therapeutics ... and characterization of drug targets from brain circuits ... key technology, optogenetics, allows the control of individual ...
(Date:12/18/2013)... , Dec. 18, 2013  EndoChoice announced today it will ... Healthcare Conference.  Mark Gilreath , Founder and CEO ... summarizing five consecutive years of quarterly revenue growth. ... 15, 2014 at 930am in the Elizabethan C meeting ... Francisco.  The conference will take place Monday, January 13, ...
(Date:12/18/2013)... ANGELES , Dec. 18, 2013 ... -based company, has process and utility patent applications ... If successful, Alsa will hold patents ... preparations directly into the lungs through vaporization, or ... and e-cigarettes, and in addition, adds Alsa,s proprietary ...
Breaking Medicine Technology:Circuit Therapeutics and Boehringer Ingelheim announce signature of a research partnership agreement to discover new approaches to treating psychiatric disorders 2Circuit Therapeutics and Boehringer Ingelheim announce signature of a research partnership agreement to discover new approaches to treating psychiatric disorders 3EndoChoice To Present at J.P. Morgan Healthcare Conference 2California Company Creates Medical Device That Could Change the Course of Medicine as We Know It 2California Company Creates Medical Device That Could Change the Course of Medicine as We Know It 3
... BEIJING, June 14, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... leading China-based advanced in-vitro diagnostic ("IVD") company, today announced ... Mr. Xiaodong Wu, Chairman and Chief Executive Officer of ... of the Company,s American Depositary Shares ("ADSs") in the ...
... June 13, 2011 Tengion, Inc. (Nasdaq: ... trial of the Company,s lead clinical product candidate, the ... a urinary diversion following bladder removal (cystectomy). Tengion is ... approach as part of its ongoing clinical trial of ...
Cached Medicine Technology:China Medical Technologies Announces the Purchase of its ADSs by Chengxuan in the Open Market 2Tengion Provides Update on Neo-Urinary Conduit Clinical Trial 2Tengion Provides Update on Neo-Urinary Conduit Clinical Trial 3Tengion Provides Update on Neo-Urinary Conduit Clinical Trial 4
(Date:12/18/2013)... of the Market for Medicinal Products (AMNOG), the German ... reassessed vemurafenib (trade name: Zelboraf), a drug for the ... melanoma. The reason for this was that the Federal ... first assessment to one year. This obliged the drug ... dossier contained additional and more recent data, but did ...
(Date:12/18/2013)... (PRWEB) December 18, 2013 ... Trends & Competitive Analysis” analyzes and studies ... in Americas, Europe, Asia Pacific, and Rest ... tables and in-depth TOC of “Ablation Technologies ... will receive 10% customization on this report. ...
(Date:12/18/2013)... The University of Adelaide has been awarded ... to develop technologies that will help researchers to create ... before. , The new Australian Research Council (ARC) ... the boundaries of biology, lasers and nanoscience, using light-based ... "Our understanding of the processes of life is limited ...
(Date:12/18/2013)... BESLER Consulting, a leading provider of ... and released a free comprehensive review of the ... final rule . , BESLER Consulting’s experts ... final rule, issued November 27, 2013 by the ... provide information to help BESLER clients better understand ...
(Date:12/18/2013)... December 18, 2013 Halftime Fitness, the ... change, today announced a new infographic. As the end ... Year's resolutions, a majority of them will fail. To ... new infographic that cites science. The goal is to ... by helping them stick to their 2014 fitness resolutions. ...
Breaking Medicine News(10 mins):Health News:Vemurafenib: Result unchanged despite new data 2Health News:Vemurafenib: Result unchanged despite new data 3Health News:Ablation Technologies Market (Radiofrequency, Cryoablation, Ultrasound, Hydrothermal) Worth $12.4 Billion by 2016 - New Report by MarketsandMarkets 2Health News:Ablation Technologies Market (Radiofrequency, Cryoablation, Ultrasound, Hydrothermal) Worth $12.4 Billion by 2016 - New Report by MarketsandMarkets 3Health News:$23 million to create a 'window into the body' 2Health News:BESLER Consulting Releases a Comprehensive Summary of the 2014 Hospital Outpatient Prospective Payment System (OPPS) Final Rule 2Health News:Halftime Fitness Launches New InfoGraphic to Help People Stick to Their 2014 Fitness Resolutions 2
... 20 The hospital services department at Northwest ... of Approval(TM) for health care staffing services from ... Joint Commission is the nation,s oldest and largest ... to its stand-alone dialysis centers, NKC has a ...
... German . , Poor sleep can be attributed ... sleep apnea a disorder in which the sleeper temporarily ... whether a patient is suffering from sleep apnea or related ... observed while sleeping for at least one night, connected to ...
... comes from confidential survey in research that highlights drugs, ... News) -- Nearly 1 in 10 retired National Football ... had used now-banned anabolic steroids while still playing. , ... use of anabolic or androgenic steroids raises a player,s ...
... Inc. (Amex: HH ) today announced that ... Christopher J. Behling, will be presenting at the Ninth ... 3, 2009 at 9:00 a.m. The conference is ... in Philadelphia, Pennsylvania. Mr. Behling,s presentation, entitled "Biometric and ...
... many children, a trip to the doctor or dentist ... the sounds, smells, and lights associated with the clinical ... This is especially true in children with developmental ... environment. A new study soon to be published ...
... may be a new way to predict mortality in ... that slowly petrifies the lungs. Most patients live only ... stable for many years, while for others, the disease ... treatment [for IPF] and many patients, if eligible, are ...
Cached Medicine News:Health News:Northwest Kidney Centers Hospital Services Department Awarded Joint Commission Certification 2Health News:Computerized mobile health support systems 2Health News:Computerized mobile health support systems 3Health News:1 in 10 Ex-NFL Players Used Steroids, Poll Reports 2Health News:1 in 10 Ex-NFL Players Used Steroids, Poll Reports 3Health News:1 in 10 Ex-NFL Players Used Steroids, Poll Reports 4Health News:Hooper Holmes to Present at the Ninth Population Health and Disease Management Colloquium 2Health News:Hooper Holmes to Present at the Ninth Population Health and Disease Management Colloquium 3Health News:New approach to dental visits may ease kids' fears 2Health News:In brief: New prognostic indicator for patients with IPF 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: